Ele Ferrannini is at the CNR Institute of Clinical Physiology, Via Roma 67, Pisa, PI 56100, Italy.Anna Solini is at the University of Pisa, Department of Clinical and Experimental Medicine, Via Roma 67, Pisa, I-56126, Italy.
Checking for direct PDF access through Ovid
Two phase III trials using the selective SGLT2 inhibitor dapagliflozin or the dual SGLT2/SGLT1 inhibitor sotagliflozin in patients with type 1 diabetes mellitus show similar clinical benefit (reduction of HbA1c, body weight, blood pressure and insulin dose). The risk of hypoglycaemia and diabetic ketoacidosis with these inhibitors can be managed by careful adjustment of insulin therapy.Refers to Garg, S. K. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N. Engl. J. Med.http://dx.doi.org/10.1056/NEJMoa1708337 (2017) | Dandona, P. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol.http://dx.doi.org/10.1016/S2213–8587(17)30308-X (2017)